Multitarget action of Benzothiazole-piperazine small hybrid molecule against Alzheimer's disease : In silico, In vitro, and In vivo investigation
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
A novel small molecule based on benzothiazole-piperazine has been identified as an effective multi-target-directed ligand (MTDL) against Alzheimer's disease (AD). Employing a medicinal chemistry approach, combined with molecular docking, MD simulation, and binding free energy estimation, compound 1 emerged as a potent MTDL against AD. Notably, compound 1 demonstrated efficient binding to both AChE and Aβ1-42, involving crucial molecular interactions within their active sites. It displayed a binding free energy (ΔGbind) -18.64± 0.16 and -16.10 ± 0.18 kcal/mol against AChE and Aβ1-42, respectively. In-silico findings were substantiated through rigorous in vitro and in vivo studies. In vitro analysis confirmed compound 1 (IC50=0.42 μM) as an effective, mixed-type, and selective AChE inhibitor, binding at both the enzyme's catalytic and peripheral anionic sites. Furthermore, compound 1 demonstrated a remarkable ability to reduce the aggregation propensity of Aβ, as evidenced by Confocal laser scanning microscopy and TEM studies. Remarkably, in vivo studies exhibited the promising therapeutic potential of compound 1. In a scopolamine-induced memory deficit mouse model of AD, compound 1 showed significantly improved spatial memory and cognition. These findings collectively underscore the potential of compound 1 as a promising therapeutic candidate for the treatment of AD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 174(2024) vom: 10. Apr., Seite 116484 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mishra, Chandra Bhushan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 30.04.2024 Date Revised 30.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2024.116484 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370544951 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370544951 | ||
| 003 | DE-627 | ||
| 005 | 20240430232244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240404s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116484 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1393.xml |
| 035 | |a (DE-627)NLM370544951 | ||
| 035 | |a (NLM)38565058 | ||
| 035 | |a (PII)S0753-3322(24)00368-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mishra, Chandra Bhushan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multitarget action of Benzothiazole-piperazine small hybrid molecule against Alzheimer's disease |b In silico, In vitro, and In vivo investigation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.04.2024 | ||
| 500 | |a Date Revised 30.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a A novel small molecule based on benzothiazole-piperazine has been identified as an effective multi-target-directed ligand (MTDL) against Alzheimer's disease (AD). Employing a medicinal chemistry approach, combined with molecular docking, MD simulation, and binding free energy estimation, compound 1 emerged as a potent MTDL against AD. Notably, compound 1 demonstrated efficient binding to both AChE and Aβ1-42, involving crucial molecular interactions within their active sites. It displayed a binding free energy (ΔGbind) -18.64± 0.16 and -16.10 ± 0.18 kcal/mol against AChE and Aβ1-42, respectively. In-silico findings were substantiated through rigorous in vitro and in vivo studies. In vitro analysis confirmed compound 1 (IC50=0.42 μM) as an effective, mixed-type, and selective AChE inhibitor, binding at both the enzyme's catalytic and peripheral anionic sites. Furthermore, compound 1 demonstrated a remarkable ability to reduce the aggregation propensity of Aβ, as evidenced by Confocal laser scanning microscopy and TEM studies. Remarkably, in vivo studies exhibited the promising therapeutic potential of compound 1. In a scopolamine-induced memory deficit mouse model of AD, compound 1 showed significantly improved spatial memory and cognition. These findings collectively underscore the potential of compound 1 as a promising therapeutic candidate for the treatment of AD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a Benzothiazole | |
| 650 | 4 | |a Dementia | |
| 650 | 4 | |a In silico | |
| 650 | 4 | |a MD simulation | |
| 650 | 4 | |a Multitarget | |
| 650 | 7 | |a Benzothiazoles |2 NLM | |
| 650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Acetylcholinesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.1.7 |2 NLM | |
| 650 | 7 | |a benzothiazole |2 NLM | |
| 650 | 7 | |a G5BW2593EP |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Scopolamine |2 NLM | |
| 650 | 7 | |a DL48G20X8X |2 NLM | |
| 650 | 7 | |a Piperazine |2 NLM | |
| 650 | 7 | |a 1RTM4PAL0V |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a amyloid beta-protein (1-42) |2 NLM | |
| 700 | 1 | |a Shalini, Shruti |e verfasserin |4 aut | |
| 700 | 1 | |a Gusain, Siddharth |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Pawan |e verfasserin |4 aut | |
| 700 | 1 | |a Kumari, Shikha |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Yong-Sung |e verfasserin |4 aut | |
| 700 | 1 | |a Kumari, Jyoti |e verfasserin |4 aut | |
| 700 | 1 | |a Moku, Bala Krishna |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Anita Kumari |e verfasserin |4 aut | |
| 700 | 1 | |a Prakash, Amresh |e verfasserin |4 aut | |
| 700 | 1 | |a Jeon, Raok |e verfasserin |4 aut | |
| 700 | 1 | |a Tiwari, Manisha |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 174(2024) vom: 10. Apr., Seite 116484 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2024 |g day:10 |g month:04 |g pages:116484 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116484 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2024 |b 10 |c 04 |h 116484 | ||